Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Next Previous
Trial Profile

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glesatinib (Primary) ; Glesatinib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors MethylGene; Mirati Therapeutics

Most Recent Events

  • 02 Dec 2022 Results assessing the maximum tolerated dose (MTD), recommended phase II dose (RP2D), and safety profile of glesatinib in patients with advanced or unresectable solid tumors published in the Targeted Oncology
  • 11 Feb 2019 Status changed from active, no longer recruiting to completed.
  • 16 Nov 2018 Results evaluating whether high MET mutant Allele Frequency of METex14 predicts tumor response to glesatinib from 265-109 and 265-101, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top